Fractyl Health, Inc. filings document regulatory, financial, governance and capital-structure disclosures for a clinical-stage metabolic therapeutics company developing Revita® and the Rejuva® gene therapy platform. Form 8-K reports furnish operating results, corporate presentations, REMAIN-1 clinical updates, Revita regulatory communications, Rejuva clinical-trial authorization for RJVA-001, and other Regulation FD disclosures.
The filing record also includes proxy materials for annual-meeting governance and equity-compensation matters, common stock and warrant disclosures, including Tranche A Common Stock Purchase Warrants, and Nasdaq continued-listing compliance notices. These documents describe the company’s public-company reporting, capital structure, stockholder voting matters and development-stage corporate disclosures.
Fractyl Health (GUTS) reported widening losses and tightening liquidity as it advances two clinical programs. Cash and cash equivalents were $22.3 million at June 30, 2025 and total assets declined to $62.0 million from $108.1 million year‑end 2024. The company recorded a net loss of $51.6 million for the six months ended June 30, 2025 versus $20.6 million a year earlier, driven largely by higher research and development spending of $40.6 million for the period.
The company had an accumulated deficit of $466.9 million and a long‑term notes payable fair value of $29.985 million. Management states that available cash of $22.3 million combined with $20.7 million of net proceeds from an August 2025 offering is not sufficient to fund the current operating plan for at least twelve months, and substantial doubt exists about the company’s ability to continue as a going concern. Operational highlights include completed enrollment in the REMAIN‑1 Revita pivotal cohorts with positive 3‑month REVEAL‑1 signals, a CTA module filing in Europe for RJVA‑001 (Rejuva) and issuance of two U.S. patents strengthening duodenal resurfacing IP.
Fractyl Health, Inc. announced that it reported its financial results for the quarter ended June 30, 2025 and provided a corporate update, and the company furnished a related press release as Exhibit 99.1 to this Current Report. The filing states the press release is being "furnished" and therefore is not deemed "filed" for Section 18 liability purposes and is not incorporated by reference into other filings unless expressly stated.
The Current Report itself does not include the underlying financial figures or detailed metrics; investors must refer to the furnished Exhibit 99.1 press release for the actual results and any numerical detail.
Fractyl Health (NASDAQ: GUTS) announced positive 3-month data from the REVEAL-1 cohort of its REMAIN-1 pivotal study, showing promising results for weight management after GLP-1 discontinuation:
- 12 out of 13 participants maintained or lost weight after stopping GLP-1 treatment and receiving a single Revita procedure
- 6 participants achieved additional weight loss
- Median weight remained stable through 3 months, contrasting with typical 5-6% rebound in studies like SURMOUNT-4
- Procedure demonstrated strong safety profile with no serious adverse effects
Additionally, the company revealed new preclinical data for its Rejuva® Smart GLP-1™ pancreatic gene therapy platform. A single dose prevented obesity and hyperglycemia in animals on high-fat diets. The company expects REMAIN-1 Midpoint Cohort data in Q3 2025 and RJVA-001 preliminary clinical data in 2026.